Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo

Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma

(2011) Dhong Hyun Lee et al.   CANCER LETTERS

AACR Highlights: Promise for Treating Pancreatic Cancer

(2011) S. Jenks   JNCI-Journal of the National Cancer Institute

Pancreatic cancer

(2011) Audrey Vincent et al.   LANCET

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers

(2011) Filip Janku et al.   PLoS One

Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma: Figure 1

(2010) Shannon A. Kavanaugh et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

(2010) U Lassen et al.   BRITISH JOURNAL OF CANCER

Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation

(2010) Margaret A. Park et al.   CANCER BIOLOGY & THERAPY

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours

(2010) Helen J. Mackay et al.   EUROPEAN JOURNAL OF CANCER

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study

(2010) Giuseppe Colucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer

(2010) Kyung Hee Lee et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

(2010) Peter J. Campbell et al.   NATURE

c-FLIP Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-Induced Apoptosis by the Histone Deacetylase Inhibitor LBH589

(2010) John Kauh et al.   PLoS One

Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer

(2010) Steffen Wedel et al.   PROSTATE

A candidate targeting molecule of insulin-like growth factor-I receptor for gastrointestinal cancers

(2010) Yasushi Adachi   WORLD JOURNAL OF GASTROENTEROLOGY

HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression

(2009) X. Huang et al.   CANCER RESEARCH

Clinical Studies of Histone Deacetylase Inhibitors

(2009) H. M. Prince et al.   CLINICAL CANCER RESEARCH

Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation

(2009) Jennifer S. Carew et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Significant Associations of Mismatch Repair Gene Polymorphisms With Clinical Outcome of Pancreatic Cancer

(2009) Xiaoqun Dong et al.   JOURNAL OF CLINICAL ONCOLOGY

Src kinases as therapeutic targets for cancer

(2009) Lori C. Kim et al.   Nature Reviews Clinical Oncology

Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors

(2008) Jung-Hyun Park et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Redox mechanisms switch on hypoxia-dependent epithelial–mesenchymal transition in cancer cells

(2008) Stefania Cannito et al.   CARCINOGENESIS

Intracellular Proadrenomedullin-Derived Peptides Decorate the Microtubules and Contribute to Cytoskeleton Function

(2008) Dan L. Sackett et al.   ENDOCRINOLOGY

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

(2008) Peter Gimsing et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells

(2008) Chie Nishioka et al.   LEUKEMIA RESEARCH

Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy

(2007) Xufang Wang et al.   EUROPEAN JOURNAL OF PHARMACOLOGY